Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 5/2011

01-10-2011

The Possible Roles of OPN-Regulated CEACAM1 Expression in Promoting the Survival of Activated T Cells and the Apoptosis of Oral Keratinocytes in Oral Lichen Planus Patients

Authors: Gui-Xiang Liu, Qi Xie, Cheng-Jun Zhou, Xiao-Ying Zhang, Bo-Long Ma, Cheng-Qin Wang, Feng-Cai Wei, Xun Qu, Shan-Zhen Sun

Published in: Journal of Clinical Immunology | Issue 5/2011

Login to get access

Abstract

Oral lichen planus is a chronic inflammatory disorder of the oral mucosa that represents T cell-mediated autoimmune diseases. The regulation and roles of carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1), a novel immune molecule, in the immunopathogenesis of T cell-mediated autoimmune diseases remain unclear. In the current paper, CEACAM1 was found to be overexpressed in peripheral T cells and epithelial cells in oral lichen planus patients. A fraction of infiltrating inflammatory mononuclear cells in the lamina propria of the oral lichen planus mucosa also expressed CEACAM1. Importantly, for the first time, CEACAM1 expression in T cells and in normal human oral keratinocytes was demonstrated to be regulated differently by osteopontin in vitro. Furthermore, the apoptosis of oral keratinocytes and activated T cells can be markedly suppressed by CEACAM1-specific monoclonal antibodies. In conclusion, OPN-regulated CEACAM1 expression may play a critical role in the immunopathogenesis of oral lichen planus.
Literature
1.
Iijima W, Ohtani H, Nakayama T, Sugawara Y, Sato E, Nagura H, et al. Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism. Am J Pathol. 2003;163:261–8.PubMedCrossRef
2.
Zhou ZT, Wei BJ, Shi P. Osteopontin expression in oral lichen planus. J Oral Pathol Med. 2008;37:94–8.PubMedCrossRef
3.
Khan A, Farah CS, Savage NW, Walsh LJ, Harbrow DJ, Sugerman PB. Th1 cytokines in oral lichen planus. J Oral Pathol Med. 2003;32:77–83.PubMedCrossRef
4.
Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med. 2002;13:350–65.PubMedCrossRef
5.
Cortes-Ramirez DA, Gainza-Cirauqui ML, Echebarria-Goikouria MA, Aguirre-Urizar JM. Oral lichenoid disease as a premalignant condition: the controversies and the unknown. Med Oral Patol Oral Cir Bucal. 2009;14:E118–22.PubMed
6.
Kim SG, Chae CH, Cho BO, Kim HN, Kim HJ, Kim IS, et al. Apoptosis of oral epithelial cells in oral lichen planus caused by upregulation of BMP-4. J Oral Pathol Med. 2006;35:37–45.PubMedCrossRef
7.
Santoro A, Majorana A, Bardellini E, Gentili F, Festa S, Sapelli P, et al. Cytotoxic molecule expression and epithelial cell apoptosis in oral and cutaneous lichen planus. Am J Clin Pathol. 2004;121:758–64.PubMedCrossRef
8.
Nagaishi T, Iijima H, Nakajima A, Chen D, Blumberg RS. Role of CEACAM1 as a regulator of T cells. Ann N Y Acad Sci. 2006;1072:155–75.PubMedCrossRef
9.
Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev. 2006;6:433–46.CrossRef
10.
Beauchemin N, Kunath T, Robitaille J, Chow B, Turbide C, Daniels E, et al. Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells. Oncogene. 1997;14:783–90.PubMedCrossRef
11.
Busch C, Hanssen TA, Wagener C, OBrink B. Down-regulation of CEACAM1 in human prostate cancer: correlation with loss of cell polarity, increased proliferation rate, and Gleason grade 3 to 4 transition. Hum Pathol. 2002;33:290–8.PubMedCrossRef
12.
Volpert O, Luo W, Liu TJ, Estrera VT, Logothetis C, Lin SH. Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. J Biol Chem. 2002;277:35696–702.PubMedCrossRef
13.
Zhou CJ, Qu X, Yang YM, Wang FF, Dong ZQ, Wang CQ, et al. CEACAM1 distribution and its effects on angiogenesis and lymphangiogenesis in oral carcinoma. Oral Oncol. 2009;45:883–6.PubMedCrossRef
14.
Poy MN, Yang Y, Rezaei K, Fernstrom MA, Lee AD, Kido Y, et al. CEACAM1 regulates insulin clearance in liver. Nat Genet. 2002;30:270–6.PubMedCrossRef
15.
Moh MC, Shen S. The roles of cell adhesion molecules in tumor suppression, cell migration: a new paradox. Cell Adh Migr. 2009;3:334–6.PubMedCrossRef
16.
Schnickmann S, Camacho-Trullio D, Bissinger M, Eils R, Angel P, Schirmacher P, et al. AP-1-controlled hepatocyte growth factor activation promotes keratinocyte migration via CEACAM1 and urokinase plasminogen activator/urokinase plasminogen receptor. J Invest Dermatol. 2009;129:1140–8.PubMedCrossRef
17.
Liu W, Wei W, Winer D, Bamberger AM, Bamberger C, Wagener C, et al. CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene. 2007;26:2747–58.PubMedCrossRef
18.
Muller MM, Singer BB, Klaile E, Obrink B, Lucka L. Transmembrane CEACAM1 affects integrin-dependent signaling and regulates extracellular matrix protein-specific morphology and migration of endothelial cells. Blood. 2005;105:3925–34.PubMedCrossRef
19.
Nagaishi T, Pao L, Lin SH, Iijima H, Kaser A, Qiao SW, et al. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity. 2006;25:769–81.PubMedCrossRef
20.
Iijima H, Neurath MF, Nagaishi T, Glickman JN, Nieuwenhuis EE, Nakajima A, et al. Specific regulation of T helper cell 1-mediated murine colitis by CEACAM1. J Exp Med. 2004;199:471–82.PubMedCrossRef
21.
Donda A, Mori L, Shamshiev A, Carena I, Mottet C, Heim MH, et al. Locally inducible CD66a (CEACAM1) as an amplifier of the human intestinal T cell response. Eur J Immunol. 2000;30:2593–603.PubMedCrossRef
22.
Cantor H, Shinohara ML. Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat Rev. 2009;9:137–41.CrossRef
23.
Gravallese EM. Osteopontin: a bridge between bone and the immune system. J Clin Invest. 2003;112:147–9.PubMed
24.
Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001;294:1731–5.PubMedCrossRef
25.
Xu G, Nie H, Li N, Zheng W, Zhang D, Feng G, et al. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest. 2005;115:1060–7.PubMed
26.
Sato T, Nakai T, Tamura N, Okamoto S, Matsuoka K, Sakuraba A, et al. Osteopontin/Eta-1 upregulated in Crohn’s disease regulates the Th1 immune response. Gut. 2005;54:1254–62.PubMedCrossRef
27.
Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol. 2007;8:74–83.PubMedCrossRef
28.
Wong CK, Lit LC, Tam LS, Li EK, Lam CW. Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005;44:602–6.CrossRef
29.
Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Blas Navarro J, et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol. 2005;158:231–9.PubMedCrossRef
30.
Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000;287:860–4.PubMedCrossRef
31.
Briese J, Oberndorfer M, Patschenik C, Schulte HM, Makrigiannakis A, Loning T, et al. Osteopontin is colocalized with the adhesion molecule CEACAM1 in the extravillous trophoblast of the human placenta and enhances invasion of CEACAM1-expressing placental cells. J Clin Endocrinol Metab. 2005;90:5407–13.PubMedCrossRef
32.
van der Meij EH, van der Waal I. Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications. J Oral Pathol Med. 2003;32:507–12.PubMedCrossRef
33.
Fromowitz FB, Viola MV, Chao S, Oravez S, Mishriki Y, Finkel G, et al. ras p21 expression in the progression of breast cancer. Hum Pathol. 1987;18:1268–75.PubMedCrossRef
34.
Rahmoun M, Moles JP, Pedretti N, Mathieu M, Fremaux I, Raison-Peyron N, et al. Cytokine-induced CEACAM1 expression on keratinocytes is characteristic for psoriatic skin and contributes to a prolonged lifespan of neutrophils. J Invest Dermatol. 2009;129:671–81.PubMedCrossRef
35.
Griffiths NJ, Bradley CJ, Heyderman RS, Virji M. IFN-gamma amplifies NFkappaB-dependent Neisseria meningitidis invasion of epithelial cells via specific upregulation of CEA-related cell adhesion molecule 1. Cell Microbiol. 2007;9:2968–83.PubMedCrossRef
36.
Markel G, Seidman R, Cohen Y, Besser MJ, Sinai TC, Treves AJ, et al. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology. 2009;126:186–200.PubMedCrossRef
37.
Chen CJ, Lin TT, Shively JE. Role of interferon regulatory factor-1 in the induction of biliary glycoprotein (cell CAM-1) by interferon-gamma. J Biol Chem. 1996;271:28181–8.PubMedCrossRef
38.
Deng GH, Chen ZL, Chen HB, Cheng J. Significance of cell immunoreactions and cell apoptosis in oral lichen planus. Hua xi kou qiang yi xue za zhi=Huaxi kouqiang yixue zazhi=West China journal of stomatology. 2009;27:256–9.PubMed
39.
Roda G, Dahan S, Mezzanotte L, Caponi A, Roth-Walter F, Pinn D, et al. Defect in CEACAM family member expression in Crohn’s disease IECs is regulated by the transcription factor SOX9. Inflamm Bowel Dis. 2009;15:1775–83.PubMedCrossRef
40.
Shiohara T, Mizukawa Y, Takahashi R, Kano Y. Pathomechanisms of lichen planus autoimmunity elicited by cross-reactive T cells. Curr Dir Autoimmun. 2008;10:206–26.PubMedCrossRef
41.
Arnold R, Seifert M, Asadullah K, Volk HD. Crosstalk between keratinocytes and T lymphocytes via Fas/Fas ligand interaction: modulation by cytokines. J Immunol. 1999;162:7140–7.PubMed
42.
Lobo EO, Zhang Z, Shively JE. Pivotal advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19-mediated adhesion of B cells in a PI3K-dependent manner. J Leukoc Biol. 2009;86:205–18.PubMedCrossRef
43.
Singer BB, Klaile E, Scheffrahn I, Muller MM, Kammerer R, Reutter W, et al. CEACAM1 (CD66a) mediates delay of spontaneous and Fas ligand-induced apoptosis in granulocytes. Eur J Immunol. 2005;35:1949–59.PubMedCrossRef
44.
Yu Q, Chow EM, Wong H, Gu J, Mandelboim O, Gray-Owen SD, et al. CEACAM1 (CD66a) promotes human monocyte survival via a phosphatidylinositol 3-kinase- and AKT-dependent pathway. J Biol Chem. 2006;281:39179–93.PubMedCrossRef
45.
N’Guessan PD, Vigelahn M, Bachmann S, Zabel S, Opitz B, Schmeck B, et al. The UspA1 protein of Moraxella catarrhalis induces CEACAM-1-dependent apoptosis in alveolar epithelial cells. J Infect Dis. 2007;195:1651–60.PubMedCrossRef
46.
Houde C, Roy S, Leung N, Nicholson DW, Beauchemin N. The cell adhesion molecule CEACAM1-L is a substrate of caspase-3-mediated cleavage in apoptotic mouse intestinal cells. J Biol Chem. 2003;278:16929–35.PubMedCrossRef
47.
Bascones-Ilundain C, Gonzalez-Moles MA, Esparza-Gomez G, Gil-Montoya JA, Bascones-Martinez A. Importance of apoptotic mechanisms in inflammatory infiltrate of oral lichen planus lesions. Anticancer Res. 2006;26:357–62.PubMed
48.
Oliveira-Ferrer L, Tilki D, Ziegeler G, Hauschild J, Loges S, Irmak S, et al. Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. Cancer Res. 2004;64:8932–8.PubMedCrossRef
49.
Phan D, Cheng CJ, Galfione M, Vakar-Lopez F, Tunstead J, Thompson NE, et al. Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis. Cancer Res. 2004;64:3072–8.PubMedCrossRef
50.
Kammerer R, Riesenberg R, Weiler C, Lohrmann J, Schleypen J, Zimmermann W. The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma. J Pathol. 2004;204:258–67.PubMedCrossRef
51.
Laack E, Nikbakht H, Peters A, Kugler C, Jasiewicz Y, Edler L, et al. Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J Clin Oncol. 2002;20:4279–84.PubMedCrossRef
52.
O’Regan AW, Chupp GL, Lowry JA, Goetschkes M, Mulligan N, Berman JS. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J Immunol. 1999;162:1024–31.PubMed
53.
Zhao F, Zhang Y, Wang H, Jin M, He S, Shi Y, et al. Blockade of osteopontin reduces alloreactive CD8+ T cell-mediated graft-versus-host disease. Blood. 2011;117:1723–33.PubMedCrossRef
Metadata
Title
The Possible Roles of OPN-Regulated CEACAM1 Expression in Promoting the Survival of Activated T Cells and the Apoptosis of Oral Keratinocytes in Oral Lichen Planus Patients
Authors
Gui-Xiang Liu
Qi Xie
Cheng-Jun Zhou
Xiao-Ying Zhang
Bo-Long Ma
Cheng-Qin Wang
Feng-Cai Wei
Xun Qu
Shan-Zhen Sun
Publication date
01-10-2011
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 5/2011
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-011-9552-4

Other articles of this Issue 5/2011

Journal of Clinical Immunology 5/2011 Go to the issue

OriginalPaper

Baseline Immune Phenotypes and CD4+ T Lymphocyte Responses to Antiretroviral Therapy in Younger versus Older HIV-infected Individuals

OriginalPaper

Decreased Expression in Nuclear Factor-κB Essential Modulator Due to a Novel Splice-Site Mutation Causes X-linked Ectodermal Dysplasia with Immunodeficiency

OriginalPaper

Inheritance Pattern and Clinical Aspects of 93 Iranian Patients with Chronic Granulomatous Disease

OriginalPaper

Altered Peripheral Invariant Natural Killer T Cells in Atopic Dermatitis

OriginalPaper

Defective T Cell Chemotaxis to Sphingosine 1-Phosphate and Chemokine CCL21 in Idiopathic T Lymphocytopenia

OriginalPaper

KRN/I-Ag7 Mouse Arthritis Is Independent of Complement C3
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits